Secukinumab Market Size, Share & Revenue Outlook 2032
According to a newly published market research report by 24LifeSciences , global secukinumab market was valued at USD 4.5 billion in 2024 and is projected to reach USD 7.8 billion by 2032 , growing at a compound annual growth rate (CAGR) of 6.8% during the forecast period 2025–2032 . Secukinumab, commercially known as Cosentyx , is a fully human monoclonal antibody that selectively targets and neutralizes interleukin-17A (IL-17A), a key cytokine involved in inflammatory processes. It represents a cornerstone biologic therapy approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its mechanism of action, focusing on a specific inflammatory pathway, has demonstrated significant efficacy in achieving rapid and sustained skin clearance, reducing joint damage, and improving quality of life for patients, solidifying its critical role in dermatology and rheumatology. Download a Free Sample Report (PDF): https://www.24lifesc...